Clinical Trial Update: A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GFH018 in combination with toripalimab and concurrent chemoradiotherapy for stage III non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GFH018 (GFH018)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: NSCLC, Stage III | Phase 2 | Status: COMPLETED